Health News
Latest health news and updates
Total: 19
Sanofi Expands Collaboration with Dren Bio to Co-Develop Next-Generation B Cell Depletion Therapies
Sanofi has entered into a strategic partnership with Dren Bio to develop innovative B cell depletion therapies aimed at treating autoimmune diseases. The deal includes significant financial incentives for Dren Bio, reflecting the potential value of the collaboration in advancing therapeutic options in this area.
Dai Rui Bio's RN3161 Obesity Treatment Completes First Cohort Dosing in Phase I Clinical Trial
Rona Therapeutics has successfully completed the first cohort dosing of its obesity treatment RN3161 in a Phase I clinical trial, showing promising safety and tolerability results. This achievement marks a significant milestone for the company's INHBE project, with further cohorts anticipated to conclude by 2026.
Junshi Bioscience: JS212 Clinical Trial Approved
Junshi Bioscience has received FDA approval for its clinical trial of JS212, a bispecific antibody conjugate aimed at treating advanced solid tumors. This development marks a significant step in the company's efforts to address serious cancer conditions.
Jiuzan Medical: U.S. Subsidiary's Quadrupole and Tripole Testing Products Receive FDA Pre-Market Notification
Jiuzan Medical has announced that its U.S. subsidiary, iHealth Labs Inc., has received FDA pre-market notifications for two types of testing products. These include home and professional test kits for quadrupole and tripole testing of various respiratory viruses, allowing for their sale in the U.S. market.
Aikang Guobin 'Missed Diagnosis' Controversy Official Investigation Conclusion: No Evidence of Medical Examination Fraud Found, Involved Clinics Penalized; Cancer Patient Lawyer Claims to Authenticate Medical Records
The Beijing Municipal Health Commission has concluded that there is no evidence of fraud in the medical examinations conducted by Aikang Guobin, although two clinics involved faced penalties for regulatory violations. Cancer patient lawyer Zhang Xiaoling continues to dispute the authenticity of her medical records and has expressed willingness to authenticate them once Aikang Guobin provides complete documentation. Aikang Guobin has also initiated legal action against Zhang for defamation.
Having a Baby Will Essentially Cost Nothing! Striving to Achieve This by Next Year! Latest Disclosure from the National Healthcare Security Administration
The National Healthcare Security Administration announced plans to eliminate out-of-pocket expenses for childbirth by next year, aiming to enhance maternity and long-term care insurance. By 2025, all provinces are expected to include assisted reproductive projects in healthcare insurance, with several provinces already providing full coverage for childbirth expenses.
10 Questions to Understand the Dual Directory of Commercial and Basic Medical Insurance: What Impact Will It Have on Ordinary People's Drug Reimbursement?
The recent updates to China's medical insurance drug directory have introduced 114 new drugs, including innovative treatments for cancer and chronic diseases. The simultaneous release of a Commercial Insurance Innovative Drug Directory aims to enhance access to high-value medications, addressing the needs of patients who may not be covered by basic medical insurance. This dual directory system is expected to improve drug affordability and accessibility for ordinary citizens.
Climbing the Peak of Scientific Research, Building a Health Defense Line — Remembering Zhou Binghua, a Civilian Staff Member at the Sports Medicine Center of the Southwest Hospital of the Army Medical University
Professor Zhou Binghua from the Sports Medicine Center of the Southwest Hospital of the Army Medical University is dedicated to addressing military training injuries through innovative research and clinical practices. His work has led to significant advancements in shoulder joint treatment, benefiting soldiers and enhancing their recovery capabilities. Zhou also emphasizes the importance of talent cultivation in the medical field.
Bridging the 'Last Mile' Between High-Priced Innovative Drugs and Patients
The National Healthcare Security Administration has introduced a commercial health insurance innovative drug directory that includes 19 high-value drugs, aiming to improve accessibility for patients. This move reflects the evolving role of commercial insurance in China's healthcare system, but challenges remain in ensuring these drugs reach patients effectively. Key barriers include standardization of coverage, payment coordination, and service integration.
Mercury Thermometers to Be Completely Banned from Production: What’s Behind This Decision
China will ban the production of mercury thermometers and sphygmomanometers starting January 1, 2026, due to health and environmental concerns. The ban aligns with the Minamata Convention on Mercury, which aims to reduce mercury exposure and its harmful effects on humans and ecosystems.
Mercury Thermometers to Be Completely Banned from Production: What Is the Reason Behind It?
China will ban the production of mercury thermometers and sphygmomanometers starting January 1, 2026, due to health and environmental concerns. The decision aligns with the Minamata Convention on Mercury, which addresses the toxicity and non-degradability of mercury, posing significant risks to human health and the ecosystem. Alternatives like electronic thermometers are considered safer and more user-friendly.
Major Breakthrough! Self-paying for a single injection costs hundreds of thousands; 5 cancer drugs included in commercial insurance, renowned pharmaceutical executive: We have been waiting for 4 years
The 2025 Innovative Drug High-Quality Development Conference announced the inclusion of five cancer drugs in the Commercial Insurance Innovative Drug Catalog, marking a significant advancement in patient access to high-cost treatments. The National Medical Insurance Catalog added 114 new drugs, enhancing the coverage of innovative therapies in China. This dual-track payment framework aims to improve the accessibility and affordability of innovative drugs for patients.